Experimental antibody cocktail offers hope for rabies patients with no other options

NCT ID NCT07706907

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This program provides access to SYN023, a combination of two lab-made antibodies (zamerovimab and mazorelvimab) designed to neutralize the rabies virus. It is for people in the United States with confirmed or suspected life-threatening rabies who cannot join other studies or access approved treatments. The antibodies are given alongside standard rabies care, and the goal is to offer a potential treatment when no alternatives exist.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a dual monoclonal antibody cocktail (zamerovimab and mazorelvimab) targeting the rabies virus
What this could lead to
If effective, this could provide a new treatment option for people with life-threatening rabies, a disease that is almost always fatal once symptoms appear.
What could go wrong
This is an expanded access program, not a formal trial, so evidence of benefit is limited. Rabies is extremely difficult to treat, and the antibodies may not change the outcome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RABIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.